Enhance MD vs GoodRx (Foundayo + Zepbound KwikPen)
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Enhance MD
Best for lab-monitored compounded GLP-1 with mandatory video visitStarting at $49/mo
GoodRx (Foundayo + Zepbound KwikPen)
Best for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmaciesStarting at $149/mo
Side-by-Side Comparison
| Feature | Enhance MD | GoodRx (Foundayo + Zepbound KwikPen) |
|---|---|---|
| Overall Score | ✓8.6/10 | 8.4/10 |
| Starting Price | ✓$49/mo | $149/mo |
| Editorial Rating | ✓4.3 ★ /5 | 4.2 ★ /5 |
| Features | 6 features | 6 features |
| States Available | 39 | ✓50 |
| Compounded | ✓ Yes | — |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Enhance MD
Pros
- ✓Baseline and ongoing metabolic lab panels (CMP, lipids, TSH, HbA1c) at Quest Diagnostics every 6 months — a rigor most compounded GLP-1 providers skip entirely
- ✓Mandatory one-on-one video visit with a US-licensed MD or NP before the first prescription — not a pure-async questionnaire model
- ✓Three pricing tiers including a combined semaglutide + tirzepatide Elite plan ($322/mo ongoing) — useful for patients plateaued on a single GLP-1
- ✓LegitScript-certified 503A pharmacy network: Tru Meds Rx, Strive Pharmacy, Pharmacy Hub
- ✓Aggressive first-month intro pricing: $49 on Core, $99 on Advanced, $189 on Elite
- ✓Unlimited clinician messaging and dose-adjustment support included
Cons
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro option
- ✗Not available in 10 states: Alabama, Arkansas, Georgia, Hawaii, Louisiana, Mississippi, Missouri, South Carolina, Tennessee, West Virginia
- ✗Mandatory lab work adds 5–10 days to onboarding vs. async-only competitors
- ✗No insurance accepted — cash pay, HSA/FSA eligible
- ✗First-month intro pricing resets to full tier rate after 30 days — the $49/$99/$189 numbers are not the ongoing cost
GoodRx (Foundayo + Zepbound KwikPen)
Pros
- ✓$149/month self-pay price for FDA-approved brand-name Foundayo (orforglipron) — matches the lowest available discounted cash price at launch and is dramatically cheaper than typical retail brand-GLP-1 pricing
- ✓$299/month self-pay for FDA-approved Zepbound KwikPen — significantly under the typical Lilly cash list price
- ✓Honored at 70,000+ US pharmacies nationwide — by far the largest brick-and-mortar redemption network of any GLP-1 distribution channel we cover
- ✓No telehealth membership fee — you bring your own prescription and present the discount card at the pharmacy counter
- ✓Brand-name FDA-approved medication, not compounded — no compounding-pharmacy quality variability or FDA non-evaluation disclaimer
- ✓Pharmaceutical manufacturer-direct pricing model — Lilly is delivering the discounted cash price directly through GoodRx, not a third-party negotiation
Cons
- ✗Requires a valid prescription — GoodRx is a discount card, not a telehealth provider. You still need a clinician to write the script (your existing PCP, an endocrinologist, or a separate telehealth visit)
- ✗Self-pay only — does not coordinate with insurance benefits or apply toward insurance deductibles
- ✗Pricing applies only to the lowest Foundayo dose at the headline number; higher doses may carry different pricing not disclosed in the launch
- ✗Does not include compounded GLP-1s — if you want compounded semaglutide or tirzepatide, this is not the channel
- ✗GoodRx is publicly traded (NASDAQ: GDRX) and pricing is subject to change as Lilly's manufacturer-sponsored coupon program evolves
Our Verdict
Enhance MD edges out GoodRx (Foundayo + Zepbound KwikPen) with a higher overall score of 8.6/10 and is particularly strong for lab-monitored compounded GLP-1 with mandatory video visit. GoodRx (Foundayo + Zepbound KwikPen) remains a solid alternative, especially if you're looking for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.